Determination ofin vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma

[1]  P. Alken,et al.  Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT) , 2004, Urological research.

[2]  C. Stief,et al.  In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a , 2004, Urological Research.

[3]  Y. Homma,et al.  Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. , 1994, European urology.

[4]  C. Logothetis,et al.  Phase II Study of Interferon-α and Chemotherapy (5-Fluorouracil and Mitomycin C) in Metastatic Renal Cell Cancer , 1992 .

[5]  C. Logothetis,et al.  Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. , 1992, The Journal of urology.

[6]  B. Rotman,et al.  Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy. , 1991, Cancer investigation.

[7]  S. Wadler,et al.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. , 1990, Cancer research.

[8]  G. Murphy,et al.  An assessment of the current use of human interferons in therapy of urological cancers. , 1989, The Journal of urology.

[9]  J. Klijn,et al.  Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. , 1989, Journal of Urology.

[10]  Todd Mb,et al.  Therapeutic options in renal cell carcinoma. , 1989 .

[11]  T. Niijima,et al.  Alpha interferon therapy for renal cell carcinoma: summary of four collaborative trials. Cancer Research Committee. , 1989, Progress in clinical and biological research.

[12]  A. Sicignano,et al.  Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. , 1989, European urology.

[13]  M. Beksac,et al.  A rapid drug sensitivity assay for neoplasmatic cells , 1988, Medical oncology and tumor pharmacotherapy.

[14]  J. Buckner,et al.  Phase I Study of Difluoromethylornithine in Combination with Recombinant α2a-Interferon , 1988 .

[15]  H. Muss.  The role of biological response modifiers in metastatic renal cell carcinoma. , 1988, Seminars in oncology.

[16]  J. Buckner,et al.  Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon. , 1988, Cancer research.

[17]  D. Vugrin.  Systemic therapy of metastatic renal cell carcinoma. , 1987, Seminars in nephrology.

[18]  D. D. Hoff.  In vitro predictive testing: the sulfonamide era , 1987 .

[19]  E. Silverberg,et al.  Cancer statistics, 1987 , 1987, CA: a cancer journal for clinicians.

[20]  S. Krown.  Therapeutic options in renal-cell carcinoma. , 1985, Seminars in oncology.

[21]  D. V. Von Hoff,et al.  Clinical correlations with the human tumor cloning assay. , 1985, Cancer investigation.

[22]  M. Lieber.  Soft agar colony formation assay for in vitro chemotherapy sensitivity testing of human renal cell carcinoma: Mayo Clinic experience. , 1984, The Journal of urology.

[23]  Pontes Je.  Adjunctive treatment of renal cell carcinoma. , 1983 .

[24]  J. Pontes.  Adjunctive treatment of renal cell carcinoma. , 1983, International advances in surgical oncology.

[25]  G. Murphy,et al.  Current status of the therapy of advanced renal carcinoma , 1977, Journal of surgical oncology.